Deck Therapeutics is a startup based in the United States.
Deck Therapeutics is a company headquartered in the United States.
Deck Therapeutics is a biopharmaceutical company developing THDG3, a semi-synthetic intravenous omega-3 fatty acid glyceride emulsion designed as a neuroprotectant for hypoxic‑ischemic brain injuries such as neonatal hypoxic‑ischemic encephalopathy and ischemic stroke; the compound was developed at Columbia University.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.